Name of the Procedure:

• Common Name: Injection of Recombinant Factor VIII (Afstyla)
• Technical/Medical Term: Injection, Factor VIII, (Antihemophilic Factor, Recombinant), (Afstyla), 1 I.U. (J7210)

Summary

This procedure involves the injection of a recombinant form of Factor VIII called Afstyla, which is essential for blood clotting. It is used to prevent or treat bleeding episodes in patients with Hemophilia A, a genetic disorder characterized by deficient or defective Factor VIII.

Purpose

• Medical Conditions Addressed: Hemophilia A
• Goals: To reduce bleeding episodes, prevent bleeding complications, and improve the overall quality of life for individuals with Hemophilia A.

Indications

• Symptoms such as spontaneous bleeding, joint bleeds, or bleeding after injury or surgery.
• Patients diagnosed with Hemophilia A who require regular Factor VIII replacement therapy.

Preparation

• Pre-procedure instructions: No special preparation is usually required.
• Assessments: A blood test to determine the Factor VIII levels and confirm the diagnosis of Hemophilia A may be needed.

Procedure Description

1. The healthcare provider will clean the injection site with an antiseptic.
2. Afstyla is prepared and drawn into a syringe under sterile conditions.
3. The injection is administered intravenously, usually in the arm.
4. Post-injection, the site may be monitored for any immediate reactions.

• Tools/Equipment: Syringe, antiseptic solution, Afstyla medication.
• Anesthesia/Sedation: Not required.

Duration

The injection process itself typically takes less than 10 minutes.

Setting

The procedure is usually performed in a hospital, outpatient clinic, or at home after proper training.

Personnel

Typically administered by:

• Healthcare professionals such as nurses, or by trained patients/caregivers.

Risks and Complications

• Common Risks: Mild pain, swelling, or redness at the injection site.
• Rare Risks: Allergic reactions, inhibitor development (where the body starts neutralizing Factor VIII), blood clots.

Benefits

• Reduces the frequency of bleeding episodes.
• Provides better control of bleeds when they occur.
• Improves quality of life by allowing participation in normal activities.

Recovery

• Post-procedure care: Monitor the injection site for any signs of infection or adverse reactions.
• Recovery Time: Immediate return to normal activity is usually possible.
• Follow-Up: Regular follow-up appointments may be needed to adjust dosage and monitor Factor VIII levels.

Alternatives

• Other Options: Plasma-derived Factor VIII, other recombinant Factor VIII products, gene therapy (in select cases), desmopressin (for mild cases).
• Pros and Cons: Plasma-derived products may carry a slightly higher risk of virus transmission, while gene therapy is still in experimental stages and not widely available.

Patient Experience

• During the Procedure: A mild prick of the needle, generally minimal discomfort.
• After the Procedure: Patients can resume normal activities swiftly; any mild pain at the injection site can be managed with over-the-counter pain relief if necessary. Regular monitoring and follow-up ensure the treatment is working effectively.